CSPC Pharmaceutical Group Limited — Earnings Release 2004

Nov 29, 2004

Listed Company Information

Listed Company Information
CHINA PHARMA<01093> - Results Announcement China Pharmaceutical Group Limited announced on 29/11/2004: (stock code: 01093 ) Year end date: 31/12/2004 Currency: HKD Auditors' Report: N/A Interim report reviewed by: Both Audit Committee and Auditors (Unaudited ) (Unaudited ) Last Current Corresponding Period Period from 01/01/2004 from 01/01/2003 to 30/09/2004 to 30/09/2003 Note ('000 ) ('000 ) Turnover : 1,710,887 1,897,190 Profit/(Loss) from Operations : 218,499 542,266 Finance cost : (17,209) (18,556) Share of Profit/(Loss) of Associates : N/A N/A Share of Profit/(Loss) of Jointly Controlled Entities : 3,110 5,081 Profit/(Loss) after Tax & MI : 184,926 450,678 % Change over Last Period : -59 % EPS/(LPS)-Basic (in dollars) : 0.1202 0.299 -Diluted (in dollars) : N/A 0.2936 Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit/(Loss) after ETD Items : 184,926 450,678 3rd Quarter Dividend : NIL NIL per Share (Specify if with other : N/A N/A options) B/C Dates for 3rd Quarter Dividend : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for : N/A Current Period B/C Dates for Other Distribution : N/A Remarks: 1. The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the year ended December 31, 2003. 2. The calculation of the basic and diluted earnings per share is based on the following data: Nine months ended September 30, 2004 2003 Profit attributable to shareholders HK$184,926,000 HK$450,678,000 ============== ============== Weighted average number of ordinary shares for the purpose of basic earnings per share 1,538,124,661 1,507,464,295 ============== Effect of dilutive potential ordinary shares in respect of share options 27,410,297 -------------- Weighted average number of ordinary shares for the purpose of diluted earnings per share 1,534,874,592 ============== No diluted earnings per share is presented for the nine months ended September 30, 2004 as there was no potential ordinary shares in issue during the period.